A detailed history of Macquarie Group LTD transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 229,482 shares of RARE stock, worth $11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
229,482
Previous 220,317 4.16%
Holding current value
$11 Million
Previous $10.3 Million 8.31%
% of portfolio
0.01%
Previous 0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$37.42 - $51.61 $342,954 - $473,005
9,165 Added 4.16%
229,482 $9.43 Million
Q1 2024

May 14, 2024

SELL
$43.02 - $53.69 $168,595 - $210,411
-3,919 Reduced 1.75%
220,317 $10.3 Million
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $222,110 - $344,330
7,000 Added 3.22%
224,236 $10.7 Million
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $54,754 - $73,162
1,568 Added 0.73%
217,236 $7.74 Million
Q2 2023

Aug 14, 2023

SELL
$37.35 - $52.15 $27.5 Million - $38.4 Million
-735,522 Reduced 77.33%
215,668 $9.95 Million
Q1 2023

May 15, 2023

SELL
$36.99 - $48.71 $6.74 Million - $8.88 Million
-182,222 Reduced 16.08%
951,190 $38.1 Million
Q4 2022

Feb 21, 2023

BUY
$33.72 - $46.33 $472,653 - $649,407
14,017 Added 1.25%
1,133,412 $52.5 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $353,006 - $584,280
8,834 Added 0.8%
1,119,395 $46.4 Million
Q2 2022

Aug 15, 2022

BUY
$45.8 - $85.4 $1.49 Million - $2.78 Million
32,537 Added 3.02%
1,110,561 $66.3 Million
Q1 2022

May 16, 2022

BUY
$62.2 - $84.4 $9.57 Million - $13 Million
153,852 Added 16.65%
1,078,024 $78.3 Million
Q4 2021

Feb 11, 2022

SELL
$73.71 - $87.86 $523,119 - $623,542
-7,097 Reduced 0.76%
924,172 $77.7 Million
Q3 2021

Nov 12, 2021

SELL
$77.92 - $102.4 $187,631 - $246,579
-2,408 Reduced 0.26%
931,269 $84 Million
Q2 2021

Aug 13, 2021

SELL
$92.19 - $115.71 $8.47 Million - $10.6 Million
-91,862 Reduced 8.96%
933,677 $89 Million
Q1 2021

May 14, 2021

SELL
$106.9 - $167.73 $15.1 Million - $23.7 Million
-141,122 Reduced 12.1%
1,025,539 $117 Million
Q4 2020

Feb 16, 2021

SELL
$84.4 - $177.39 $16.5 Million - $34.7 Million
-195,692 Reduced 14.36%
1,166,661 $162 Million
Q3 2020

Nov 13, 2020

SELL
$72.98 - $90.0 $12 Million - $14.8 Million
-164,662 Reduced 10.78%
1,362,353 $112 Million
Q2 2020

Aug 11, 2020

SELL
$46.91 - $78.22 $4.48 Million - $7.47 Million
-95,487 Reduced 5.89%
1,527,015 $119 Million
Q1 2020

May 15, 2020

BUY
$33.8 - $62.9 $7.04 Million - $13.1 Million
208,293 Added 14.73%
1,622,502 $72.1 Million
Q4 2019

Feb 14, 2020

BUY
$36.08 - $45.83 $6.43 Million - $8.17 Million
178,196 Added 14.42%
1,414,209 $60.4 Million
Q3 2019

Nov 14, 2019

BUY
$42.5 - $63.11 $18.6 Million - $27.7 Million
438,720 Added 55.03%
1,236,013 $52.9 Million
Q2 2019

Aug 14, 2019

BUY
$54.93 - $74.36 $7.17 Million - $9.71 Million
130,561 Added 19.58%
797,293 $50.6 Million
Q1 2019

May 15, 2019

BUY
$39.87 - $69.36 $12.4 Million - $21.5 Million
310,530 Added 87.18%
666,732 $46.2 Million
Q4 2018

Feb 15, 2019

BUY
$38.89 - $77.3 $3.64 Million - $7.24 Million
93,625 Added 35.66%
356,202 $15.5 Million
Q3 2018

Nov 15, 2018

BUY
$71.81 - $90.15 $18.9 Million - $23.7 Million
262,577 New
262,577 $20 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.35B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.